Last year, Cryoport Inc generated 79.68M USD for its biggest-performing segment, Life Science products. The Americas made the largest contribution, accounting for 131.26M USD last year. For the latest quarter, Cryoport Inc reported the revenue of 22.36M USD for the period ending 2026-06-30, which came from the top-performing segment, BioLogistics solutions. Americas contributed the highest revenue, at 36.89M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Life Science products

BioLogistics solutions

BioStorage/Bioservices

Biopharmaceutical

Animal health

Reproductive medicine

FY2025

FY2024

FY2023

FY2022

FY2021

FY2019

FY2018

Life Science products

79.68M(45.23%)

74.72M(47.67%)

89.17M(19.11%)

--(--)

BioLogistics solutions

78.14M(44.35%)

67.02M(42.75%)

130.50M(27.97%)

--(--)

BioStorage/Bioservices

18.36M(10.42%)

15.03M(9.58%)

13.59M(2.91%)

--(--)

Biopharmaceutical

--(--)

192.58M(41.28%)

193.88M(81.71%)

180.20M(80.95%)

27.00M(87.35%)

16.48M(83.95%)

Animal health

--(--)

30.38M(6.51%)

33.47M(14.10%)

33.35M(14.98%)

996.00K(3.22%)

976.00K(4.97%)

Reproductive medicine

--(--)

10.29M(2.21%)

9.93M(4.19%)

9.05M(4.07%)

2.91M(9.43%)

2.17M(11.07%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Americas

Europe & Middle East & Africa (EMEA)

Asia Pacific

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Americas

131.26M(74.50%)

113.55M(72.43%)

127.21M(54.54%)

128.21M(54.03%)

120.27M(54.03%)

49.55M(62.97%)

28.80M(84.85%)

17.88M(91.09%)

Europe & Middle East & Africa (EMEA)

25.13M(14.27%)

27.02M(17.24%)

60.88M(26.10%)

42.16M(17.77%)

59.33M(26.65%)

20.32M(25.82%)

4.52M(13.33%)

1.36M(6.96%)

Asia Pacific

19.78M(11.23%)

16.20M(10.33%)

45.16M(19.36%)

66.91M(28.20%)

43.00M(19.32%)

8.82M(11.21%)

618.00K(1.82%)

384.00K(1.96%)